The invention relates to a one-pot reaction for the preparation of a compound of formula (I). The compound of formula (I) may be further transformed into picropodophyllin and derivatives thereof.
##STR00001##
|
##STR00022##
wherein:
R, which may be the same or different, is selected from the group consisting of OH, OCH3, OCH2CH3, F, Cl, CH3 and CF3, and n is 0, 1, 2, 3, or 4;
the process comprising cyclization of a compound of formula (II)
##STR00023##
wherein:
R and n are as defined for formula (I); and
P is an activating group;
in the presence of
i. a base;
ii. a protic solvent, or a mixture of a protic and an aprotic solvent; and
iii. a transition metal component;
wherein the process is performed under Heck reaction conditions.
2. The process according to
##STR00024##
to yield a compound of formula (III)
##STR00025##
3. The process according to
5. The process according to
7. The process according to
8. The process according to
9. The process according to
10. The process according to
11. The process according to
12. The process according to
13. The process according to
14. The process according to
15. The process according to
16. The process according to
17. The process according to
18. The process according to
19. The process according to
20. The process according to
21. The process according to
22. The process according to
23. The process according to
24. The process according to
25. The process according to
26. A method of making picropodophyllin, the method comprising utilizing a process according to
|
|||||||||||||||||||||||||||||||||||||||||||||||||
This application is the U.S. national stage of PCT/SE2011/051034, filed on Aug. 30, 2011, which claims priority to U.S. provisional patent application Ser. No. 61/378,435, filed on Aug. 31, 2010 and to Swedish patent application no. SE 1050894-3, filed on Aug. 31, 2010.
The present invention relates to a process for the preparation of cyclic compounds which may be further transformed into picropodophyllin and derivatives thereof. More specifically, the invention relates to a one-pot reaction for the preparation of polycyclic lignans involving ring closure and epimerization.
Picropodophyllin is a compound belonging to the class of compounds denominated cyclolignans. The chemical structure of picropodophyllin is complex with a fused cyclic ring system and four adjacent chiral centra. The stereochemistry of the lactone ring exhibits a cis configuration by having two beta carbon-carbon bonds, i.e. the 8-9 and 8′-9′ bonds are located in or above the plane of the carbon ring. The hydroxy group and the trimethoxy benzyl ring are connected to the 7 and 7′ carbons, respectively, by alpha-bonds.
##STR00002##
For a long time, picropodophyllin attracted little interest, since it was believed to possess no or low biological activity. In contrast, its stereoisomer podophyllotoxin, which has a trans configuration in the lactone ring, has been studied for decades due to its cytotoxic properties. Podophyllotoxin is also the starting material for the synthesis of Etoposide and other topoisomerase II inhibitors.
##STR00003##
However, research has revealed that picropodophyllin does indeed exhibit interesting biological properties.
In WO 02/102804 it is disclosed that picropodophyllin is a specific and potent inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and may be used in the treatment of IGF-1R dependent diseases such as various types of cancer, for instance malignant melanoma, Ewing's sarcoma, breast cancer, prostate cancer and leukemia, as well as in the treatment of psoriasis, arteriosclerosis and acromegaly. It is also mentioned that picropodophyllin may be used to potentiate the effects of anti-cancer drugs.
WO 2007/097707 discloses the use of picropodophyllin in the prophylaxis or treatment of diabetes mellitus type 2, nephropathy, retinopathy, macular degeneration, retinopathy of prematurity, central retinal vein occlusion, branch retinal vein occlusion, rubeotic glaucoma, thyroid eye disease, corneal graft rejection and corneal chemical burns; and for contraception.
WO 2009/157858 discloses the use of picropodophyllin for prophylaxis or treatment of diseases or conditions characterized by a hyperactive immune system such as rheumatoid arthritis, Crohn's disease, ulcerative colitis, multiple sclerosis, Alzheimer's disease, asthma, eczematous dermatitis, and graft rejection following transplantation.
Usually, picropodophyllin is obtained from its stereoisomer podophyllotoxin by epimerization. The major source of podophyllotoxin is several podophyllum species which mainly can be found in China. Because of the ease of extraction, Podophyllum emodi is a highly preferred plant, but this plant is difficult to cultivate and is becoming extinct in the wild which has caused the Chinese government to give this plant the highest level of protection. Podophyllum peltatum and Podophyllum versipelle constitute other plant sources of podophyllotoxin, but yield less pure podophyllotoxin upon extraction. Extraction of the podophyllum species yields podophyllotoxin, which has to be handled with great care because of its cytotoxic properties. The lack of easy access to the podophyllum species, the need for cautious handling of the poisonous plants and the cytotoxic podophyllotoxin, and the fact that podophyllum species are also used for extraction of other biologically active compounds are all factors that contribute to a high cost of goods and uncertain availability of podophyllotoxin as well as picropodophyllin.
A method converting podophyllotoxin into picropodophyllin is disclosed in Journal of Pharmaceutical Sciences, Vol. 75, No. 11, November 1986, Ole Buchardt et al., pages pp. 1076-1080. The yield of pure picropodophyllin is reported to be 78%.
The complex structures of podophyllotoxin and picropodophyllin have made them attractive targets for organic chemists interested in total synthesis of structurally complex compounds exhibiting biological activity, sometimes also with the aim of finding a synthetic route suitable to being performed on a large scale. Most of the published total synthesis aim at synthesizing podophyllotoxin, the drawbacks of which have been indicated above, which is subsequently epimerized into picropodophyllin at the end of the reaction sequence. For instance, synthetic routes involving epimerization of podophyllotoxin into picropodophyllin are described in Angew. Chem., Int. Ed., 2008, 47, p. 7557 and Org. Lett., 2009, 11(3), p. 597. It is a disadvantage to perform a crucial chemical reaction step at the end of a long reaction sequence since the value of the material, i.e. the compound undergoing transformations in the reaction sequence, increases with each reaction step and a failure at a late stage of the synthesis will therefore be expensive. Some publications mention synthetic routes wherein picropodophyllin is formed without going via podophyllotoxin. For instance, Angew. Chem., Int. Ed., 2008, 47, p. 7557 mentions such a route, but this route also produces a substantial amount of a by-product.
The synthetic route to podophyllotoxin (which can then be isomerized to picropodophyllin) used in Angew. Chem., Int. Ed., 2008, 47, p. 7557 is depicted in Scheme I.
##STR00004##
Another publication mentioning a synthetic route for formation of picropodophyllin without going via podophyllotoxin is described in Chem. Commun., 2004, p. 184. However, when the inventors attempted to repeat this synthetic route problems were encountered during the synthesis of the enantiopure sulfoxide starting material. The difficulties of making the sulfoxide were confirmed by the authors of the Chem. Comm. article.
Thus, there remains a need for improved synthesis of picropodophyllin and derivatives thereof.
Abbreviations
It is an object of the present invention to overcome or at least mitigate some of the disadvantages associated with the prior art.
The present invention is based on the unexpected finding that it is possible to epimerize and cyclize a compound of Formula (V) in a one-pot reaction using Heck reaction conditions.
##STR00005##
The resulting product is a compound of Formula (III) having a cis configuration in the lactone ring by having two beta carbon-carbon bonds, i.e. the 8-9 and 8′-9′ bonds are located above the plane of the carbon ring.
##STR00006##
The compound of Formula (III) may be used in the synthesis of, for instance, picropodophyllin and analogues thereof.
In this document, the expression Heck reaction conditions is understood to mean a stoichiometric or catalytic amount of one or more transition metal compounds, such as palladium or nickel compounds, which may be the same or different, in the presence of a base. The transition metal compounds, such as palladium or nickel compounds, may be added to the reaction mixture or generated in situ in the reaction mixture. Typically, the transition metal is palladium. Further, the palladium compound may be Pd(0), i.e. palladium in the oxidation state zero, Pd(0) attached to one or more ligands or palladium in other oxidation states capable of generating an active Heck catalyst. The Heck reaction is described in the textbook Advanced Organic Chemistry, 5th to; Smith, M. B., March, J.; Section 14-19, pages 931-932. Nickel transition metal compounds may be Ni(0) or Ni(II). For examples of Heck reactions using nickel catalysts, see for instance Li; Pei, W.; Chen, S. J. Chem. Res. 2006, pp. 388-389. and Inamoto, K.; Kuroda, J.; Danjo, T.; Sakamoto, T. Synlett 2005, pp. 1624-1626. and for a review, see: Ackermann, L.; Born, R. Mizoroki-Heck Reactions with Metals Other than Palladium. In The Mizoroki-Heck Reaction; Oestreichq, M., Ed.; John Wiley & Sons Ltd.: Chichester, U. K., 2009; pp 383-403. (DOI:10.1002/9780470716076.ch10)
The one-pot reaction presents the advantages of determining the stereochemistry of the lactone ring into the desired cis configuration at an early stage of the reaction sequence, thereby shortening the synthetic route to picropodophyllin as well as avoiding handling of the cytotoxic podophyllotoxin.
One aspect the present invention provides a one-pot process for the preparation of a compound of Formula (I)
##STR00007##
##STR00008##
wherein
In one aspect of the invention the transition metal component is selected from Pd(0), a compound containing Pd(II), a compound containing Pd(0), a mixture of compounds containing Pd(II) and Pd(0), and a mixture of Pd(0) and a compound containing Pd(II) and/or Pd(0).
In a further aspect of the invention, the transition metal component is Ni(0) or Ni(II), such as Nickel acetate tetrahydrate —Ni(II)(OAc)2.4H2O having the CAS number 6018-89-9 or Nickel(II) acetylacetonate —Ni(II)(acac)2 having the CAS #3264-82-2
In yet an aspect of the invention, the transition metal component is the Hermann-Beller catalyst, having the chemical name trans-Di(μ-acetato)bis[o-(di-o-tolyl-phosphino)benzyl]dipalladium(II) and the CAS #172418-32-5.
In still an aspect of the invention, the transition metal component is Pd-118 (PdCl2(dtbpf)), having the chemical name 1,1′-Bis(di-tert-butylphosphino)ferrocene]dichloropalladium(II) and the CAS #95408-45-0.
In one aspect of the invention, the transition metal complex is Pd(dppf)Cl2.CH2Cl2 (Pd(dppf).DCM), having the chemical name [1,1′-Bis(diphenylphosphino)ferrocene]-dichloropalladium(II).
While not wishing to be bound by any specific theory, it is believed that the activating group P acts by activating the palladium catalyzed oxidative addition step of Heck cyclization,
In one aspect of the invention there is provided a process wherein R in Formula (I) and (II) is OCH3.
In yet an aspect of the invention there is provided a process as herein described, for the preparation of a compound of Formula (III)
##STR00009##
comprising cyclization of a compound of Formula (IV)
##STR00010##
wherein P is an activating group.
In one aspect of the invention there is provided a process as herein described, wherein the activating group P is selected from the group consisting of trifluoromethanesulfonate, methanesulfonate, ethanesulfonate, benzenesulfonate, toluenesulfonate and 4-nitrobenzenesulfonate.
In still an aspect of the invention there is provided a process as herein described, wherein the base is an inorganic base, such as an inorganic base selected from the group consisting of K2CO3, Na2CO3, KHCO3, NaHCO3, NaOH, Cs2CO3, KOH, NaOH, Na3PO4, Na2HPO4, K3PO4, K2HPO4, and NH4OH.
In yet an aspect of the invention the base may be an amine base such as ammonia, trimethyl amine, triethyl amine and diisopropyl ethylamine.
In yet an aspect of the invention there is provided a process as herein described, wherein the compound containing Pd(0) is selected from the group consisting of Pd(dppf).DCM, tetrakis(triphenylphosphine)Pd(0), Pd2(dba)3, dichlorobis(triphenylphosphine)palladium(0), palladium(II) acetate, palladium(II) acetate triphenylphosphine, palladium(II) chloride, palladium(II) chloride triphenylphosphine and palladium black.
In one aspect of the invention, there is provided a process as herein described, wherein the solvent is a protic solvent.
In one aspect of the invention there is provided a process as herein described, wherein the protic solvent is selected from the group consisting of methanol, ethanol, propanol, isopropanol, butanol and tert-butanol.
In one aspect of the invention there is provided a process as herein described, wherein the solvent comprises 0.001-50 vol-% of water.
In still an aspect of the invention there is provided a process as herein described, wherein the solvent comprises 2-20 vol-% of water.
In an aspect of the invention there is provided a process as herein described, wherein the solvent comprises 0.001-20 vol-% of water.
In yet an aspect of the invention, the solvent comprises 5 vol-% of water.
In one aspect of the invention there is provided a process as herein described, further comprising heating during the cyclization of the compound of Formula (II).
In one aspect of the invention there is provided a method of making picropodophyllin or derivatives thereof, comprising a process according to any previous aspect and as herein described.
In a further aspect of the invention, there is provided a method of making 4′-demethoxy-picropodophyllin comprising a process according to any previous aspect and as herein described.
##STR00011##
In an aspect of the invention, the heating during the cyclization of the compound of Formula (II) may take place at a temperature of from room temperature to 150° C.
In yet an aspect of the invention, the heating during the cyclization of the compound of Formula (II) may take place at a temperature of from 40° C. to 120° C.
In a further aspect of the invention, the heating during the cyclization of the compound of Formula (II) may take place at a temperature of from 30° C. to 100° C.
In one aspect of the invention, the heating during the cyclization of the compound of Formula (II) may take place at a temperature of from 40° C. to 90° C.
In one aspect of the invention, the heating during the cyclization of the compound of Formula (II) may take place at a temperature of from 60° C. to 80° C.
In one aspect of the invention, the heating during the cyclization of the compound of Formula (II) may take place at a temperature of from 50° C. to 80° C.
In still an aspect of the invention, the heating during the cyclization of the compound of Formula (II) may take place at a temperature of from 70° C. to 80° C.
In a further aspect of the invention, the cyclization of the compound of Formula (II) may take place in a mixture of solvents. It is to be understood that such solvents may be protic or aprotic. Examples of protic solvents that may be used in the cyclization are methanol, ethanol, propanol, isopropanol, butanol and tert-butanol. Examples of aprotic solvents that may be used in the cyclization are acetonitrile, dimethylsulfoxide, tetrahydrofuran, dimethylformamide, N-methylpyrrolidone and dioxane.
In one aspect of the invention, the compound of Formula (V) is cyclized into the compound of Formula (III) as depicted in Scheme II below.
##STR00012##
The cyclization reaction of the invention was successfully used in the synthesis of picropodophyllin as depicted in Scheme III below.
##STR00013##
In still an aspect of the invention, the compound of Formula (V) is cyclized into the compound of Formula (III) as depicted in Scheme IV below.
##STR00014##
In yet an aspect of the invention, the cyclization reaction of the invention was successfully used in the synthesis of picropodophyllin as depicted in Scheme V below.
##STR00015##
In Schemes II and III, the trifluoromethanesulfonate derivative V used as starting material was synthesized in the same way as compound 6c depicted in Scheme I. Comparison with Scheme I leading to podophyllotoxin (which then requires an isomerization step to picropodophyllin) shows that the process of the invention shortens the reaction sequence to picropodophyllin by one step, and also presents the advantage of having the epimerization to picropodophyllin at an early stage.
All commercial starting materials were purchased from Sigma-Aldrich, Fluke, TCl and Merck and were used as received without further purification.
The above aspects and embodiments may be combined with any other embodiment, aspect or claim of the invention described hereinbefore or hereinafter.
The invention is illustrated, but not limited, by the following Examples.
General Example Experimental Procedures
All solvents used were of HPLC grade or better, when anhydrous conditions were required an excess of 3 Å molecular sieves were added to a portion of the solvent at least 24 h before use to ensure dryness. 1H Nuclear magnetic resonance (NMR) was recorded on a Bruker Advance DPX 400 spectrometer at 400.1 MHz. Low-resolution electrospray ionization mass spectra were obtained using an Agilent mass spectrometer, in either positive or negative ionization mode. Flash chromatography was performed on Merck silica gel 60 (230-400 mesh). Analytical LCMS data were obtained with an Agilent mass spectrometer; Agilent 1100 system; ACE 3 C8 column, (50×3.0 mm, 5 μM); Gradient: 10-97% acetonitrile in water/0.1% TFA, in 3 min (flow: 1.0 mL/min); or Agilent mass spectrometer; Agilent 1100 system; Xterra C18 column (50×3.0 mm, 5 μM); Gradient: 10-97% acetonitrile in water/10 mM NH4HCO3 at pH10, in 3 min; (flow: 1.0 mL/min). Names of chemical structures were determined using Marvin Sketch 5.2.6, ChemAxon.
##STR00016##
6-{[(4R)-4-ethenyl-2-oxooxolan-3-yl](3,4,5-trimethoxyphenyl)methyl}-2H-1,3-benzodioxol-5-yl trifluoromethanesulfonate (2.20 g, 3.93 mmol) (obtained according to Stadler, D.; Bach, T. Angew. Chem., Int. Ed., 2008, 47, 7557-7559.) was dissolved in 95% ethanol. Pd(dppf).DCM (0.96 g, 1.18 mmol) and K2CO3 (1.63 g, 11.8 mmol) were added and after short stirring the reaction was heated at 80° C. for 60 min. The reaction mixture was filtered through a pad of silica topped with celite and evaporated. The residue was dissolved in dichloromethane and filtered again through a pad of silica topped with celite. The crude product obtained by evaporation in vacuo (0.83 g, 51%) was isolated as a yellow-orange solid. Silica chromatography eluting with Pentane:EtOAc 1:1→1:2. LCMS: ACE 3 C8, 50×3.0 mm, 10%-97% methanol in 0.1% TFA in water, 1 mL/min; 80%, MS: 428 (100), 411, 429. 1H-NMR (400 MHz, CDCl3): δ [ppm]=3.67-3.82 (m, 3H), 3.85 (s, 6H), 3.90 (s, 3H), 3.98 (app. s, 1H), 4.0 (d, 1H), 4.95 (d, 1H), 5.11 (d, 1H), 5.92 (app. s, 1H), 5.94 (app. s, 1H), 6.23 (s, 1H), 6.50-6.55 (m, 2H), 6.85 (s, 1H).
##STR00017##
(11S,15S)-16-Methylidene-10-(3,4,5-trimethoxyphenyl)-4,6,13-trioxatetracyclo[7.7.0.0^{3,7}.0^{11,15}]hexadeca-1,3(7),8-trien-12-one obtained in Example 1 (0.730 g, 1.22 mmol) and N-methyl morpholine oxide (50 wt-% solution in water, 1.25. mL, 5.34 mmol) were suspended in dichloromethane (60 mL). Osmium tetroxide (4 wt-% solution in water, 0.37 mL, 0.060 mmol) was added to the suspension. The mixture was stirred vigorously at rt. After most of starting material had been consumed (over week-end), NalO4 (0.52 g, 2.44 mmol) was added and the reaction was stirred for an additional 30 min. The reaction was quenched by addition of aqueous sodium thiosulfate (50 mL) and the phases were separated. The aqueous phase was extracted with dichloromethane (2×50 mL) and the combined organic layers were washed with brine, dried over Na2SO4, filtered and evaporated to give 630 mg (85% yield) of the product in 75% purity. Another batch of ketone has been purified by filtration through a pad of silica topped with celite and eluting with Heptane:EtOAc 1:1. LCMS: ACE 3 C8, 50×3.0 mm, 10% to 97% acetonitrile in 0.1% TFA in water, 1 mL/min; Rt=2.091.
##STR00018##
(11R,15S)-16-(3,4,5-trimethoxyphenyl)-4,6,13-trioxatetracyclo[7.7.0.0^{3,7}.0^{11,15}]hexadeca-1,3(7),8-triene-10,14-dione obtained in Example 2 (848 mg, 2.06 mmol) was suspended in methanol (50 mL) and cooled to 0° C. Sodium borohydride (117 mg, 3.08 mmol) was added and the suspension stirred over night. The reaction mixture was stirred at 0° C. for 3 h and was quenched by addition of 0.1 M hydrochloric acid. The product precipitated as white solid. The crude product was washed with methanol-water and purified by silica chromatography Pentane:EtOAc 1:3→1:5 to 221 mg of the title product (26%). LCMS analysis using ACE 3 C8, 50×3.0 mm, 10%-97% acetonitrile in 0.1% TFA in water, 1 mL/min showed 97% chromatographic purity; MS [M-OH−]+397 and [M+1]+415. 1H-NMR (400 MHz, DMSO-d6): d [ppm]=2.50-2.58 (m, 1H, overlapping with solvent residue signal), 3.42 (dd, 1H), 3.70 (s, 3H), 3.76 (s, 6H), 3.92 (d, 1H), 3.98 (bs, 1H), 4.36 (d, 1H), 4.41 (dd, 1H), 4.51 (dd, 1H), 5.42 (app. d, 2H), 6.03 (s, 1H), 6.50 (s, 2H), 7.08 (s, 1H).
##STR00019##
6-{[(4R)-4-ethenyl-2-oxooxolane-3-yl](3,4,5-trimethoxyphenyl)methyl)-2H-1,3-benzodioxol-5-yl trifluoromethanesulfonate (obtained according to Stadler, D.; Bach, T. Angew. Chem., Int. Ed., 2008, 47, 7557-7559.) (6.70 g, 11.95 mmol) was dissolved in 95% ethanol (250 mL). Anhydrous sodium carbonate (3.80 g, 35.85 mmol) and Herrmann-Beller catalyst (CAS#172418-32-5) (0.45 g, 0.60 mmol) were added and the resulting mixture heated at reflux for 15 h. Upon cooling, the mixture was filtered through a pad of Celite and eluted with ethanol (100 mL). The filtrate was concentrated to give a solid (3.08 g). Yield: 63% The obtained material was used as such in the next step. An analytical sample was obtained by silica chromatography eluting with pentane:ethylacetate 1:1→1:2.
LCMS: ACE 3 C8, 50×3.0 mm, 10%-97% methanol in 0.1% TFA in water, 1 mL/min; 80%, MS: 428 (100), 411, 429
1H-NMR (400 MHz, CDCl3): δ [ppm]=3.67-3.82 (m, 3H), 3.85 (s, 6H), 3.90 (s, 3H), 3.98 (app. s, 1H), 4.0 (d, 1H), 4.95 (d, 1H), 5.11 (d, 1H), 5.92 (app. s, 1H), 5.94 (app. s, 1H), 6.23 (s, 1H), 6.50-6.55 (m, 2H), 6.85 (s, 1H)
##STR00020##
(11S,15S)-16-methylidene-10-(3,4,5-trimethoxyphenyl)-4,6,13-trioxatetracyclo[7.7.0.0^{3,7}.0^{11,15}]hexadeca-1,3(7),8-trien-12-one obtained in Example 4 (6.00 g, 14.63 mmol) and N-methyl-morpholine-oxide (50 wt-% solution in water, 9.01 mL, 43.90 mmol) were suspended in dichloromethane (100 mL). Osmium tetroxide (4 wt-% solution in water, 4.54 mL, 0.73 mmol) was added. The mixture was stirred at r.t. for 4 h. Sodium perioidate (6.26 g, 29.26 mmol) was added and the mixture stirred at r.t. for 1 h. The reaction was quenched by aqueous sodium thiosulfate (100 mL) and the phases separated. The water-phase was extracted with dichloromethane (3×100 mL) and the combined organic phases washed with brine, dried with magnesium sulfate, filtered and evaporated. The material was purified by filtration over a pad of silica gel, which was eluted with 50% ethylacetate in hexane. The filtrate was concentrated to give a solid (5.43 g). Yield: 90%
The obtained material was used as such in the next step.
LCMS: ACE 3 C8, 50×3.0 mm, 10%-97% methanol in 0.1% TFA in water, 1 mL/min; 80%, MS: 413 (100)
##STR00021##
(11R,15S)-16-(3,4,5-trimethoxyphenyl)-4,6,13-trioxatetracyclo-[7.7.0.0^{3,7}.0^{11,15}]hexadeca-1,3(7),8-triene-10,14-dione obtained in analogy with Example 5 (40 g, 97.09 mmol) was suspended in methanol (700 mL) and the resulting mixture cooled to 0° C. Sodium borohydride (7.39 g, 194.18 mmol) was added in portions over 2 h and the resulting mixture stirred at r.t. overnight. Aqueous ammonium acetate (1 M, 200 mL) was added and the formed precipitate collected by filtration. The filter-cake was washed with 50 vol-% methanol in water (4×50 mL) and dried to constant weight under vacuum overnight to give a solid. The mother liquid was extracted with dichloromethane (3×500 mL); the organic solution was washed with brine and dried over anhydrous sodium sulfate. After filtration and concentration, the residue was combined with the dried solid and recrystallized from dichloromethane and hexane to afford a white solid (32.3 g). Yield: 80.4%
LCMS ACE 3 C8, 50×3.0 mm, 10%-97% acetonitrile in 0.1% TFA in water, 1 mL/min showed 97% chromatographic purity, MS [M+NH4]+432 (100), [M-OH]+397
1H-NMR (400 MHz, DMSO-d6): δ [ppm]=2.50-2.58 (m, 1H, overlapping with solvent residue signal), 3.42 (dd, 1H), 3.70 (s, 3H), 3.76 (s, 6H), 3.92 (d, 1H), 3.98 (bs, 1H), 4.36 (d, 1H), 4.41 (dd, 1H), 4.51 (dd, 1H), 5.42 (app. d, 2H), 6.03 (s, 1H), 6.50 (s, 2H), 7.08 (s, 1H)
Specific rotation: [α]28D (c=0.27 in chloroform)+13.0°
Bremberg, Ulf, Axelsson, Magnus, Linden, Auri, Von Kieseritzky, Fredrik
| Patent | Priority | Assignee | Title |
| Patent | Priority | Assignee | Title |
| 5013851, | Dec 05 1985 | Bristol-Myers Company | Intermediates for the production of podophyllotoxin and related compounds |
| 20130317099, | |||
| 20130331445, | |||
| CN101389326, | |||
| CN101492704, | |||
| EP522173, | |||
| JP2005500300, | |||
| JP6009642, | |||
| WO2102804, | |||
| WO2007097707, | |||
| WO2009100349, | |||
| WO2009157858, |
| Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
| Aug 30 2011 | Alexar AB | (assignment on the face of the patent) | / | |||
| Mar 01 2013 | LINDEN, AURI | Axelar AB | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 029987 | /0970 | |
| Mar 02 2013 | VON KIESERITZKY, FREDRIK | Axelar AB | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 029987 | /0970 | |
| Mar 04 2013 | BREMBERG, ULF | Axelar AB | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 029987 | /0970 | |
| Mar 06 2013 | AXELSSON, MAGNUS | Axelar AB | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 029987 | /0970 |
| Date | Maintenance Fee Events |
| Sep 06 2018 | M2551: Payment of Maintenance Fee, 4th Yr, Small Entity. |
| Nov 14 2022 | REM: Maintenance Fee Reminder Mailed. |
| May 01 2023 | EXP: Patent Expired for Failure to Pay Maintenance Fees. |
| Date | Maintenance Schedule |
| Mar 24 2018 | 4 years fee payment window open |
| Sep 24 2018 | 6 months grace period start (w surcharge) |
| Mar 24 2019 | patent expiry (for year 4) |
| Mar 24 2021 | 2 years to revive unintentionally abandoned end. (for year 4) |
| Mar 24 2022 | 8 years fee payment window open |
| Sep 24 2022 | 6 months grace period start (w surcharge) |
| Mar 24 2023 | patent expiry (for year 8) |
| Mar 24 2025 | 2 years to revive unintentionally abandoned end. (for year 8) |
| Mar 24 2026 | 12 years fee payment window open |
| Sep 24 2026 | 6 months grace period start (w surcharge) |
| Mar 24 2027 | patent expiry (for year 12) |
| Mar 24 2029 | 2 years to revive unintentionally abandoned end. (for year 12) |